Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

Profitability Depends On Research Staff

May 25, 2015 | A version of this story appeared in Volume 93, Issue 21

March 16, page 13: The map showing which states have policies on the disclosure of fracking chemicals should have shown New Mexico in blue to indicate that the Land of Enchantment has this kind of rule. Kudos to reader Leiming Li from Sugar Land, Texas, for pointing out the error (C&EN, May 18, page 2). View an up-to-date version of this map online at http://cenm.ag/frackingmap.

It seems like every few months C&EN publishes an article about pharmaceutical firms cutting research staff. Management in most industrial concerns is appropriately focused on profitability, but cutting research staff to save money is somewhat of an oxymoron.

Pfizer let most of its staff go when it acquired Parke-Davis/Warner-Lambert and Pharmacia Upjohn, research groups that developed Lipitor and ibuprofen. Did someone say profitability? Duh.

Michael Wider
Pleasant Ridge, Mich.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.